An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Radiographic Progression Free Survival (rPFS)

  Measured over: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approx 43 months

Changes Tremor has spotted